Stock Spotlight Archives - Page 2 of 400

ThursdayJun 18, 2026 12:29 pm

QualityStocksNewsBreaks – Why Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Is ‘One to Watch’

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. A clinical-stage oncology company , Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is focused on advancing a new class of DNA Damage Response (“DDR”) therapies and developing artificial intelligence-driven precision oncology solutions. “The company is leading the development of Polynucleotide Kinase Phosphatase (‘PNKP’) inhibitors, an emerging category of DDR therapeutics designed to target DNA repair pathways involved in cancer survival and resistance,” reads a recent article. “Through its dual-platform approach, Onco-Innovations combines proprietary drug development with AI-enabled technologies intended to support oncology research, clinical development, patient stratification and evidence generation.” To…

WednesdayJun 17, 2026 3:26 pm

QualityStocksNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Aligns with Growing Shift Toward Predictive, Precision Medicine

Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on personalized, data-driven cardiovascular care powered by artificial intelligence, epigenetics and genetic insights. “Through its proprietary platform and expanding testing capabilities, the company is pursuing a future in which prevention becomes more accessible, scalable and actionable before life-threatening cardiac events occur,” reads a recent article. “The company’s vision reflects a broader shift taking place across the healthcare industry toward predictive and precision medicine. Cardio Diagnostics envisions a healthcare system where every patient receives individualized care informed by their unique molecular insights and where heart disease is no longer the world’s leading killer. Achieving that goal…

WednesdayJun 17, 2026 2:02 pm

QualityStocksNewsBreaks – Why Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) Is ‘One to Watch’

Disseminated on behalf of Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) and may include paid advertising. Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) develops AI-powered platforms focused on accelerating chemistry research and development across pharmaceutical, defense, public safety, and industrial applications. “The company is working at the intersection of AI and chemistry, building tools intended to help organizations navigate increasingly complex scientific and development challenges,” reads a recent article. “Redwood AI’s platforms are built on proprietary AI models and analytical infrastructure that improve as datasets and platform usage expand.” To view the full article, visit https://ibn.fm/1uqAl About Redwood AI Corp. Redwood AI uses advanced artificial…

TuesdayJun 16, 2026 1:47 pm

QualityStocksNewsBreaks – Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) (FSE: P6U) Builds Gateway to High-Growth Opportunities in Space and Aerospace

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) (FSE: P6U) and may include paid advertising. Structured as a publicly traded investment issuer, Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) (FSE: P6U) provides investors with exposure to private space and aerospace companies that would otherwise remain inaccessible to most retail participants. “In a TechMediaWire podcast interview, Chief Executive Officer Etienne Moshevich described Planet’s evolution over the past two and a half years, explaining how the company transformed from approximately $5 million in cash and assets into a platform now holding roughly $20 million while shifting toward a dedicated space-focused investment strategy,” reads…

TuesdayJun 16, 2026 1:25 pm

QualityStocksNewsBreaks – Earth Science Tech Inc. (ETST) Positioned at Intersection of Telemedicine, Pharmacy, Healthcare Services

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its significant transformation over the past several years, positioning as a diversified holding company focused on pharmaceutical compounding, telemedicine, healthcare services, and strict capital allocation. “The company recently completed a vertically integrated telehealth and pharmacy ecosystem through the launch of MyOnlineConsultation.com, with telemedicine capabilities supporting patient acquisition, while pharmacy operations drive high-margin recurring prescription-based revenue streams,” reads a recent article. “Above all, Earth Science Tech emphasizes balance-sheet strength and capital discipline through ongoing share repurchase initiatives designed to reduce dilution and support shareholder value.” To view the full…

TuesdayJun 16, 2026 12:57 pm

QualityStocksNewsBreaks – Why VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

VERAXA Biotech (NASDAQ: VRXA) is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. “The company is focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next wave of smart cancer therapies with curative potential and improved safety profiles,” reads a recent article. “The company is building a pipeline that includes dual-targeting antibody-drug conjugates (‘ADCs’) and T-cell engagers (‘TCEs’) predominantly based on its patented BiTAC concept. This concept is designed to improve the…

FridayJun 12, 2026 2:35 pm

QualityStocksNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Harnesses AI, Genetics and Epigenetics to Advance Cardiovascular Risk Detection

Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discusses the urgent need for more effective tools to identify risk earlier and guide personalized intervention strategies for cardiovascular disease. The piece reads, “Cardio Diagnostics is rising to the challenge by developing a suite of clinical, population health and biopharma solutions designed to leverage artificial intelligence (‘AI’), epigenetics and genetics to improve cardiovascular disease prevention, detection and management… The company’s platform is built around the integration of genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights from blood-based testing. Cardio Diagnostics currently offers two clinical solutions, Epi+Gen…

ThursdayJun 11, 2026 3:15 pm

QualityStocksNewsBreaks – MindWave Innovations Inc. (NYSE American: APUS) Taps Growing Demand for Yield-Generating Solutions

MindWave Innovations (NYSE American: APUS) is positioning at the forefront of a structural shift in corporate finance: the transition from static treasury holdings to intelligent, yield-generating digital asset infrastructure. “The company’s latest milestone, up to $100 million PIPE financing alongside the activation of 1,000 BTC, highlights increasing investor conviction in Bitcoin not just as a store of value, but as a productive treasury instrument when paired with institutional-grade infrastructure,” reads a recent article. “Unlike what is obtainable with traditional corporate treasuries that depend on cash equivalents or short-duration government securities yielding modest returns, MindWave’s model introduces programmable yield strategies anchored in…

ThursdayJun 11, 2026 2:29 pm

QualityStocksNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Accelerates Development Strategy for Lead Candidate

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, was featured in a recent article that discussed the company’s efforts beginning a key phase of preclinical development for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. The publication reads, “The company is initiating a Good Laboratory Practice (‘GLP’) toxicology and pharmacology program aligned with U.S. Food and Drug Administration (‘FDA’) requirements, intended to support an Investigational New Drug (‘IND’) application and represents a necessary step before first-in-human clinical trials.…

FridayMay 29, 2026 3:50 pm

QualityStocksNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Leveraging Scalable Strategy at Santa Fe Project

Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising. Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) was featured in a recent article that discussed its positioning for growth through a scalable satellite deposit strategy. The publication reads, “As global reserve depletion continues to pressure the mining industry, companies are shifting their strategy away from expensive, standalone discoveries and toward scalable satellite deposits that can be developed alongside existing operations… Lahontan Gold is positioned to capitalize on this rapidly evolving ecosystem. The company’s flagship Santa Fe Mine project in Nevada’s Walker Lane already benefits from established infrastructure, historical…

Site Search

Company Search

Category: Stock Spotlight